<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
"http://www.w3.org/TR/REC-html40/loose.dtd">
<html>
<head>
<title>Untitled Document</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
</head>
<body>
<p>
The full EPAR for Improvac can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. <br/>
ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. <br/>
<hr/>
This summary was last updated in September 2017. <br/>
Dan is-sommarju ġie aġġornat l-aħħar f'Settembru 2017. <br/>
<hr/>
EPAR summary for the public <br/>
Sommarju tal-EPAR għall-pubbliku <br/>
<hr/>
The most common side effects with Improvac (which may affect more than 1 in 10 pigs) are injection site swelling, which gradually resolves but in 20 to 30% of animals will last for more than 6 weeks, and a short-lived increase in body temperature of around 0.5 ˚C within 24 hours of vaccination. <br/>
L-effetti sekondarji l-aktar komuni b'Improvac (li jistgħu jaffettwaw aktar minn 1 minn kull 10 ħnieżer) huma nefħa fis-sit tal-injezzjoni, li titlaq gradwalment iżda f'20 sa 30 % tal-annimali ddum għal aktar minn 6 ġimgħat, u żieda fit-temperatura tal-ġisem li ma ddumx ta' madwar 0.5 ˚C fi żmien 24 siegħa mit-tilqim. <br/>
<hr/>
The European Commission granted a marketing authorisation valid throughout the EU for Improvac on 11 May 2009. <br/>
Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal Improvac fil-11 ta' Mejju 2009. <br/>
<hr/>
Other information about Improvac? <br/>
Informazzjoni oħra dwar Improvac? <br/>
<hr/>
This is a summary of the European public assessment report (EPAR) for Improvac. <br/>
Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Improvac. <br/>
<hr/>
What are the risks associated with Improvac? <br/>
X'inhuma r-riskji assoċjati ma' Improvac? <br/>
<hr/>
The first injection is from 8 weeks of age and the second 4 to 6 weeks before slaughter. <br/>
L-ewwel injezzjoni hija mill-età ta' 8 ġimgħat u t-tieni 4 sa 6 ġimgħat qabel il-qtil. <br/>
<hr/>
The active substance in Improvac is an analogue of (similar to) gonatadotropin releasing factor (GnRF) linked to a carrier protein obtained from the bacterium Corynebacterium diphtheriae. <br/>
Is-sustanza attiva f'Improvac hija analogu ta' (simili għal) fattur li jirrilaxxa l-gonatadotropin (GnRF) marbut ma' proteina ġarriera miksuba mill-batterju Corynebacterium diphtheriae. <br/>
<hr/>
This temporarily inhibits release of steroids from the testicles, including androstenone, one of the two causes of boar taint. <br/>
Dan jinibixxi b'mod temporanju r-rilaxx ta' sterojdi mit-testikoli, inkluż androstenone, wieħed miż-żewġ kawżi ta' riħa jew togħma tal-ħanżir. <br/>
<hr/>
Androstenone and skatole levels are reduced from 4 to 6 weeks after the second injection and reduction of aggression and sexual behaviour is seen from 1 to 2 weeks after the second injection. <br/>
Il-livelli ta' androstenone u skatole jitnaqqsu minn 4 sa 6 ġimgħat wara t-tieni injezzjoni u t-tnaqqis fl-aggressjoni u fl-imġiba sesswali jidher minn ġimgħa sa ġimagħtejn wara t-tieni injezzjoni. <br/>
<hr/>
Boar taint is caused by the production and build-up of the natural compounds androstenone and skatole in the flesh of these animals. <br/>
Ir-riħa jew it-togħma tal-ħanżir tiġi kkawżata mill-produzzjoni u l-akkumulazzjoni tal-komposti naturali androstenone u skatole fil-laħam ta' dawn l-annimali. <br/>
<hr/>
Improvac works by stimulating the pig's immune system to produce antibodies against gonadotropin-releasing hormone (GnRH), part of the system that controls sexual development. <br/>
Improvac jaħdem billi jistimula s-sistema immuni tal-ħanżir biex tipproduċi antikorpi kontra ormon li jirrilaxxa l-gonatadotropin (GnRH), parti mis-sistema li tikkontrolla l-iżvilupp sesswali. <br/>
<hr/>
Improvac contains the active substance gonadotropin releasing factor (GnRF) analogue-protein conjugate. <br/>
Improvac fih is-sustanza attiva konjugat ta' analogu ta' proteina ta' fattur li jirrilaxxa gonadotropin (GnRF). <br/>
<hr/>
Improvac gonadotropin releasing factor (GnRF) analogue-protein conjugate <br/>
Improvac konjugat ta' analogu ta' proteina ta' fattur li jirrilaxxa l-gonadotropin (GnRF, gonadotropin releasing factor) <br/>
<hr/>
The first injection had a limited effect, but the second injection is followed by production of antibodies against GnRF. <br/>
L-ewwel injezzjoni kellha effett limitat, iżda t-tieni injezzjoni tiġi segwita mill-produzzjoni ta' antikorpi kontra <br/>
<hr/>
Why is Improvac approved? <br/>
Għaliex ġie approvat Improvac? <br/>
<hr/>
For the full list of restrictions and all side effects reported with Improvac, see the package leaflet. <br/>
Għal-lista sħiħa ta' restrizzjonijiet u tal-effetti sekondarji kollha rrappurtati b'Improvac, ara l-fuljett ta' tagħrif. <br/>
<hr/>
Two studies showed reduction of aggression and mounting from 1 to 2 weeks after the second injection of Improvac, while the third studied the long term effect on aggression and mounting after 4 weeks only. <br/>
Żewġ studji wrew tnaqqis ta' aggressjoni u rkib minn ġimgħa sa ġimagħtejn wara t-tieni injezzjoni ta' Improvac, filwaqt li t-tielet wieħed studja l-effett fit-tul fuq l-aggressjoni u l-irkib wara biss 4 ġimgħat. <br/>
<hr/>
These may include a temporary reduction in sex hormone levels and reduced ability to reproduce in men and in women, including problems with pregnancy. <br/>
Dawn jistgħu jinkludu tnaqqis temporanju fil-livelli tal-ormon sesswali u abbiltà mnaqqsa għar-riproduzzjoni fl-irġiel u fin-nisa, inkluż problemi fit-tqala. <br/>
<hr/>
Improvac also reduces aggressive and sexual (mounting) behaviour in pigs. <br/>
Improvac itejjeb ukoll l-imġiba aggressiva u sesswali (irkib) fil-ħnieżer. <br/>
<hr/>
In a number of field studies pigs treated with Improvac were comparable to surgically castrated pigs in terms of levels of androstenone and skatole at slaughter. <br/>
F'numru ta' studji fuq il-post, il-ħnieżer ikkurati b'Improvac kienu komparabbli għal ħnieżer kastrati b'kirurġija f'termini ta' livelli ta' androstenone u skatole mal-qtil. <br/>
<hr/>
Three field studies investigated the effectiveness of Improvac in reducing aggression and sexual behaviour in pigs. <br/>
Tliet studji fuq il-post investigaw l-effettività ta' Improvac fit-tnaqqis tal-aggressjoni u l-imġiba sesswali fil-ħnieżer. <br/>
<hr/>
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Improvac's benefits are greater than its risks and recommended that it be approved for use in the EU. <br/>
Il-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) tal-Aġenzija ddeċieda li l-benefiċċji ta' Improvac huma akbar mir-riskji tiegħu u rrakkomanda li jkun approvat għall-użu fl-UE. <br/>
<hr/>
Improvac also contains a compound derived from the sugar dextran as an adjuvant (ingredient that strengthens the immune response). <br/>
Improvac fih ukoll kompost derivat mid-dextran taz-zokkor bħala addittiv (ingredjent li jsaħħaħ ir-rispons immuni). <br/>
<hr/>
The full EPAR for Preotact can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. <br/>
ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. <br/>
<hr/>
This summary was last updated in 05-2012. <br/>
Dan is-sommarju ġie aġġornat l-aħħar fi: 05-2012. <br/>
<hr/>
Preotact significantly reduced the risk of having a vertebral fracture, in comparison with placebo: after 18 months, there were 42 vertebral fractures in the placebo group (3.37) and 17 in the Preotact group (1.32). <br/>
Preotact naqqas drastikament ir-riskju li jkun hemm ksur vertebrali, meta mqabbel ma' plaċebo: wara 18-il xahar, kien hemm 42 ksur vertebrali fil-grupp tal-plaċebo (3.37) u 17 fil-grupp ta' Preotact (1.32). <br/>
<hr/>
Preotact was compared with placebo (a dummy treatment). <br/>
Preotact tqabbel ma' plaċebo (trattament finta). <br/>
<hr/>
Preotact has been studied in one main study involving 2,532 women with postmenopausal osteoporosis. <br/>
Preotact ġie studjat fi studju li involva 2,532 mara li jbatu minn osteoporożi ta' wara l-menopawża. <br/>
<hr/>
Preotact parathyroid hormone <br/>
Preotact ormon paratirojdu <br/>
<hr/>
This is a summary of the European public assessment report (EPAR) for Preotact. <br/>
Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Preotact. <br/>
<hr/>
It is produced by a method known as ‘recombinant DNA technology': the hormone is made by a bacterium that has received a gene (DNA) that makes it able to produce it. <br/>
Dan huwa prodott b'metodu magħruf bħala ‘teknoloġija rikombinanti tad-DNA': l-ormon huwa magħmul minn batterju li jkun irċieva ġene (DNA) li jagħmilha possibbli li jipproduċih. <br/>
<hr/>
The most common side effects with Preotact (seen in more than 1 patient in 10) are hypercalcaemia (high blood calcium levels), hypercalciuria (high calcium levels in the urine) and nausea (feeling sick). <br/>
L-aktar effetti sekondarji komuni b'Preotact (li dehru f'aktar minn pazjent 1 minn kull 10) huma liperkalsemija (livelli għolja ta' kalċju fid-demm), iperkalsjurja (livelli għolja ta' kalċju fl-awrina) u nawżja (tħossok ma tiflaħx). <br/>
<hr/>
The European Commission granted a marketing authorisation valid throughout the European Union for Preotact on 24 April 2006. <br/>
Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Preotact valida fl-Unjoni Ewropea kollha fl-24 ta' April 2006. <br/>
<hr/>
The recommended dose of Preotact is 100 micrograms, given once a day as an injection under the skin into the abdomen. <br/>
Id-doża rakkomandata ta' Preotact hija ta' 100 mikrogramma, darba kuljum bħala injezzjoni taħt ilġilda fl-addome. <br/>
<hr/>
What is Preotact? <br/>
X'inhu Preotact? <br/>
<hr/>
Preotact is a medicine that contains the active substance parathyroid hormone. <br/>
Preotact huwa mediċina li fih is-sustanza attiva ormon paratirojdu. <br/>
<hr/>
• with unexplained high levels of alkaline phosphatase (an enzyme), <br/>
• persuni li jbatu minn disturbi li jaffettwa l-bilanċ tal-kalċju u l-fosfat fil-ġisem, <br/>
<hr/>
Preotact contains parathyroid hormone, which stimulates bone formation by acting on osteoblasts (bone forming cells). <br/>
Preotact taħdem bħall-ormon biex tistimula l-formazzjoni tal-għadam billi taġixxi fuq osteoblasts (ċelloli li jiffurmaw l-għadam). <br/>
<hr/>
The parathyroid hormone in Preotact is identical to the human parathyroid hormone. <br/>
L-ormon paratirojdu f'Preotact huwa l-istess bħall-ormon paratirojdu uman. <br/>
<hr/>
Patients may also need to take calcium and vitamin D supplements if they do not have enough from their diet. Preotact can be used for up to 24 months, after which patients can be treated with a bisphosphonate (a medicine that reduces bone loss). <br/>
Preotact jista' jibqa' jittieħed sa mhux aktar minn 24 xahar, imbagħad ilpazjenti jisgħu jkomplu jiġu kkurati bil-bisfosfonat (mediċina li tnaqqas it-telf tal-għadam). <br/>
<hr/>
Osteoporosis is more common in women after the menopause, when the levels of the female hormone oestrogen fall. <br/>
Finnisa, l-osteoporożi hija aktar komuni wara l-menopawża, meta l-livelli tal-ormon tan-nisa, l-estroġenu, jaqgħu. <br/>
<hr/>
When the cartridge is inserted in the special injection pen and the pen screwed together, or when the pre-filled pen is prepared for use, the powder and solvent mix to make up the solution for injection. <br/>
It-tnaqqis tar-riskju kien inqas fin-nisa li diġà kellhom vertebra miksura fil-passat, u fin-nisa li diġà kellhom skor baxx tad-densità tal-għadam meta beda l-istudju, u dan jindika li kellhom spina aktar fraġli. <br/>
<hr/>
Why has Preotact been approved? <br/>
Għaliex ġie approvat Preotact? <br/>
<hr/>
What is the risk associated with Preotact? <br/>
X'inhu r-riskju assoċjat ma' Preotact? <br/>
<hr/>
Preotact is used for the treatment of osteoporosis (a disease that makes bones fragile) in postmenopausal women who are at high risk of fractures. <br/>
Preotact wera li jnaqqas b'mod sinifikanti l-ksur vertebrali (tas-sinsla tad-dahar), iżda mhux il-ksur fil-ġenbejn. <br/>
<hr/>
• who have a bone disease that is not osteoporosis, <br/>
• persuni li għandhom marda fl-għadam li mhix l-osteoporożi, <br/>
<hr/>
The bone density was also the main measure in another study, which looked at the use of Preotact with or without alendronate (a bisphosphonate). <br/>
Id-densità tal-għadam kien ukoll il-kejl ewlieni fi studju ieħor, li ffoka fuq l-użu ta' Preotact flimkien jew mingħajr l-alendronat (bisfosfonat). <br/>
<hr/>
</body></html/>
